The latest vaccine scandal puts Beijing's plan to become a global pharmaceutical heavyweight in jeopardy, despite attempts by authorities to dispel public anger over China's drug and food safety. A Chinese woman holds up her hands as she walks past the logo of Sanofi Pasteur during an anti-vaccination rally outside its headquarters in Shanghai September 30, 2012. In 2017, China was the world's second-biggest healthcare market, worth $122.6bn, with growth predicted to reach $145bn to $175bn by 2022.
The latest vaccine scandal puts Beijing's plan to become a global pharmaceutical heavyweight in jeopardy, despite attempts by authorities to dispel public anger over China's drug and food safety. "The latest in a litany of food and drug safety scares, the Changsheng case has sparked both intense criticism of the Chinese government’s ability to regulate the space at home, and concerns about China’s recent push to market pharmaceuticals abroad", said the Council on Foreign Relations' Viola Rothschild. In 2017, China was the world's second-biggest healthcare market, worth $122.6bn, with growth predicted to reach $145bn to $175bn by 2022.